-
Article
Open Access4-1BB immunotherapy: advances and hurdles
Since its initial description 35 years ago as an inducible molecule expressed in cytotoxic and helper T cells, 4-1BB has emerged as a crucial receptor in T-cell-mediated immune functions. Numerous studies have...
-
Article
Open Access4-1BB-4-1BBL cis-interaction contributes to the survival of self-reactive CD8+ T cell
-
Article
Combined treatment with anti-HER2/neu and anti-4-1BB monoclonal antibodies induces a synergistic antitumor effect but requires dose optimization to maintain immune memory for protection from lethal rechallenge
Human epidermal growth factor receptor type 2 (HER2)-positive breast cancer that is treated with anti-HER2/neu monoclonal antibody (mAb) is not free from late recurrences. Addition of anti-4-1BB mAb to anti-HE...
-
Article
Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1
We previously found the SLC3A2-NRG1 (S-N) fusion gene in a lung adenocarcinoma specimen without known driver mutations and validated this in 59 invasive mucinous adenocarcinoma (IMA) samples. Interestingly, KRAS ...
-
Article
Open AccessAdoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rαhi CD8+ T cells
Adoptive T cell therapy (ACT) requires lymphodepletion preconditioning to eliminate immune-suppressive elements and enable efficient engraftment of adoptively transferred tumor-reactive T cells. As anti-CD4 mo...
-
Article
Open AccessChronic activation of 4-1BB signaling induces granuloma development in tumor-draining lymph nodes that is detrimental to subsequent CD8+ T cell responses
The antitumor capabilities of agonistic anti-4-1BB mAbs have made them an attractive target for tumor immunotherapy. However, the adverse side effects associated with agonist antibodies have hindered their cli...
-
Article
Open AccessDesensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression
Chimeric antigen receptor (CAR) T cell therapy is an effective method for treating specific cancers. CARs are normally designed to recognize antigens, which are highly expressed on malignant cells but not on T...
-
Article
4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8+ T cell proliferation
4-1BB (CD137) is a strong enhancer of the proliferation of CD8+ T cells. Since these cells require increased production of energy and biomass to support their proliferation, we hypothesized that 4-1BB signaling a...
-
Article
Open AccessExpression of 4-1BB and 4-1BBL in thymocytes during thymus regeneration
4-1BB, a member of the tumor necrosis factor receptor (TNFR) superfamily, is a major costimulatory receptor that is rapidly expressed on the surface of CD4+ and CD8+ T cells after antigen- or mitogen-induced acti...
-
Article
Correction: Corrigendum: 4-1BB-mediated immunotherapy of rheumatoid arthritis
Nat. Med. 10, 1088–1094 In the Figure 4 legend, “CD11c+CD8+ T or CD11c−CD8+” should read “CD11c+CD8+ or CD11c−CD8+ T cells.” In b of the Figure 5 legend, “control IgG or” should be deleted.
-
Article
4-1BB-mediated immunotherapy of rheumatoid arthritis
Collagen type II–induced arthritis is a CD4+ T-cell–dependent chronic inflammation in susceptible DBA/1 mice and represents an animal model of human rheumatoid arthritis. We found that development of this conditi...
